Cargando…

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia

Venetoclax is a promising agent in the treatment of acute myeloid leukemia (AML), though its antileukemic activity is limited to combination therapies. Mcl-1 downregulation, Bim upregulation, and DNA damage have been identified as potential ways to enhance venetoclax activity. In this study, we comb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xinyu, Su, Yongwei, Hege, Katie, Madlambayan, Gerard, Edwards, Holly, Knight, Tristan, Polin, Lisa, Kushner, Juiwanna, Dzinic, Sijana H., White, Kathryn, Yang, Jay, Miller, Regan, Wang, Guan, Zhao, Lijing, Wang, Yue, Lin, Hai, Taub, Jeffrey W., Ge, Yubin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094102/ https://www.ncbi.nlm.nih.gov/pubmed/32165486 http://dx.doi.org/10.3324/haematol.2019.233445

Ejemplares similares

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia
por: Li, Xinyu, et al.
Publicado: (2019)

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
por: Qiao, Xinan, et al.
Publicado: (2021)

Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation
por: Liu, Fangbing, et al.
Publicado: (2020)

Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia
por: Luedtke, Daniel A., et al.
Publicado: (2020)

Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic
por: Al-Mansour, Fares, et al.
Publicado: (2023)

Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth
por: Chilamakuri, Rameswari, et al.
Publicado: (2022)

CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action
por: Hu, Cheng, et al.
Publicado: (2020)

Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 attenuates TGFβ1 induced lung and tumor fibrosis
por: Zhang, Wentian, et al.
Publicado: (2020)

CUDC‐907 blocks multiple pro‐survival signals and abrogates microenvironment protection in CLL
por: Chen, Yixiang, et al.
Publicado: (2018)

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis
por: Hurrish, Katie H., et al.
Publicado: (2023)

Therapeutic Potential of CUDC-907 (Fimepinostat) for Hepatocarcinoma Treatment Revealed by Tumor Spheroids-Based Drug Screening
por: Liao, Wei, et al.
Publicado: (2021)

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2020)

CUDC-907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2
por: Tu, Tian, et al.
Publicado: (2019)

Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2021)

Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer
por: Jian, Zheng, et al.
Publicado: (2022)

Pluripotent stem cell‐based screening identifies CUDC‐907 as an effective compound for restoring the in vitro phenotype of Nakajo‐Nishimura syndrome
por: Kase, Naoya, et al.
Publicado: (2020)

CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells
por: Huegel, Julianne, et al.
Publicado: (2022)

Correction to: Pluripotent Stem Cell-Based Screening Identifies CUDC-907 as an Effective Compound for Restoring the In Vitro Phenotype of Nakajo-Nishimura Syndrome
Publicado: (2022)

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
por: Knight, Tristan, et al.
Publicado: (2019)

Enhanced Efficacy of 5-Fluorouracil in Combination with a Dual Histone Deacetylase and Phosphatidylinositide 3-Kinase Inhibitor (CUDC-907) in Colorectal Cancer Cells
por: Hamam, Rimi, et al.
Publicado: (2017)

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
por: Oki, Yasuhiro, et al.
Publicado: (2017)

Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells
por: Moertl, Simone, et al.
Publicado: (2019)

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
por: Lee, Jong Bok, et al.
Publicado: (2021)

Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia
por: Wang, Tingting, et al.
Publicado: (2019)

Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells
por: Ma, Jun, et al.
Publicado: (2017)

ONC201 induces the unfolded protein response (UPR) in high‐ and low‐grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity
por: Rumman, Marufa, et al.
Publicado: (2021)

Antileukemic effect of venetoclax and hypomethylating agents via caspase-3/GSDME-mediated pyroptosis
por: Ye, Fanghua, et al.
Publicado: (2023)

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer
por: Zhang, Lisa, et al.
Publicado: (2015)

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ((123/131)I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors
por: Grand-Guillaume, Joana, et al.
Publicado: (2023)

HDAC Inhibitor LBH589 Suppresses the Proliferation but Enhances the Antileukemic Effect of Human γδT Cells
por: He, Ying, et al.
Publicado: (2020)

Maspin expression patterns differ in the invasive versus lepidic growth pattern of pulmonary adenocarcinoma
por: Lonardo, Fulvio, et al.
Publicado: (2014)

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer
por: Zhang, Lisa, et al.
Publicado: (2016)

Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
por: Wu, Shuangshuang, et al.
Publicado: (2022)

CUDC-101 is a potential target inhibitor for the EGFR-overexpression bladder cancer cells
por: Wang, Zhenxing, et al.
Publicado: (2023)

The vulnerable primed cancer stem cells in disguise: demystifying the role of Maspin
por: Sheng, Shijie, et al.
Publicado: (2022)

Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity
por: Chougule, Anuradha, et al.
Publicado: (2013)

907. Age-stratified seroprevalence of respiratory syncytial virus in Korean population
por: Nham, Eliel, et al.
Publicado: (2023)

Antileukemic activity of novel adenosine derivatives
por: Poczta, Anastazja, et al.
Publicado: (2019)

MON-907 Silent Presentation of Urinary Bladder Paraganglioma: A Case Report
por: Kirupakaran, Johnathan, et al.
Publicado: (2020)

Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells
por: Savickiene, Jurate, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4lmuiu87q1rcjbmh0cblcq8cu1